GLP-1 drug side effects

European regulators have raised concerns about nonarteritic anterior ischemic optic neuropathy (NAION), sometimes called an eye stroke, as a rare but serious risk associated with GLP-1 drugs. A cohort study published in JAMA Network Open found that patients with type 2 diabetes taking semaglutide or tirzepatide had a higher incidence of NAION compared to those on other diabetes medications.

The World Health Organization issued its first global guidelines on childhood obesity, strongly recommending against GLP-1 weight-loss medications for children under 10, noting that starting young children on these drugs does more harm than good.

GLP-1 receptor agonists produce a spectrum of adverse effects, most commonly gastrointestinal symptoms such as nausea, vomiting, diarrhea, and constipation. These effects are typically dose-dependent and often improve with gradual titration. More serious adverse events include gallbladder disease, acute pancreatitis, and rare reports of diabetic retinopathy worsening.

Side effect profiles affect both adherence and the cost of care, as patients who discontinue due to intolerability may cycle through alternative therapies or require additional medical management.

Common and serious adverse reactions linked to GLP-1 drugs, including gastrointestinal symptoms, gallbladder issues, pancreatitis concerns, muscle loss, and long-term safety questions.

Key developments include who recommends against obesity drugs for children under 10, european regulators raise concerns about eye stroke risk with glp-1 drugs, among other significant events and policy changes.

Source: Geo Health Space